KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Debt (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Total Debt for 9 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • Quarterly Total Debt fell 34.41% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, down 34.41% year-over-year, with the annual reading at $31.1 million for FY2025, 34.41% down from the prior year.
  • Total Debt for Q4 2025 was $31.1 million at Supernus Pharmaceuticals, up from $11.2 million in the prior quarter.
  • The five-year high for Total Debt was $424.1 million in Q4 2021, with the low at $11.2 million in Q3 2025.
  • Average Total Debt over 5 years is $59.3 million, with a median of $46.6 million recorded in 2024.
  • The sharpest move saw Total Debt soared 1272.47% in 2021, then tumbled 95.02% in 2022.
  • Over 5 years, Total Debt stood at $424.1 million in 2021, then crashed by 95.02% to $21.1 million in 2022, then surged by 146.54% to $52.1 million in 2023, then fell by 9.08% to $47.3 million in 2024, then crashed by 34.41% to $31.1 million in 2025.
  • According to Business Quant data, Total Debt over the past three periods came in at $31.1 million, $11.2 million, and $30.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.